CN109195600A - 反式-[四氯双(1h-吲唑)钌(iii)酸盐]用于治疗癌症的用途 - Google Patents

反式-[四氯双(1h-吲唑)钌(iii)酸盐]用于治疗癌症的用途 Download PDF

Info

Publication number
CN109195600A
CN109195600A CN201780027237.0A CN201780027237A CN109195600A CN 109195600 A CN109195600 A CN 109195600A CN 201780027237 A CN201780027237 A CN 201780027237A CN 109195600 A CN109195600 A CN 109195600A
Authority
CN
China
Prior art keywords
cancer
patient
grp78
pharmaceutically acceptable
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780027237.0A
Other languages
English (en)
Chinese (zh)
Inventor
S·贝克维尔
J·塞图拉曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intezyne Technologies Inc
Original Assignee
Intezyne Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intezyne Technologies Inc filed Critical Intezyne Technologies Inc
Publication of CN109195600A publication Critical patent/CN109195600A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
CN201780027237.0A 2016-03-01 2017-03-01 反式-[四氯双(1h-吲唑)钌(iii)酸盐]用于治疗癌症的用途 Pending CN109195600A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662301786P 2016-03-01 2016-03-01
US62/301,786 2016-03-01
PCT/US2017/020209 WO2017151775A1 (en) 2016-03-01 2017-03-01 Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer

Publications (1)

Publication Number Publication Date
CN109195600A true CN109195600A (zh) 2019-01-11

Family

ID=59744351

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780027237.0A Pending CN109195600A (zh) 2016-03-01 2017-03-01 反式-[四氯双(1h-吲唑)钌(iii)酸盐]用于治疗癌症的用途

Country Status (8)

Country Link
US (4) US10821095B2 (https=)
EP (1) EP3423055A4 (https=)
JP (3) JP6997919B2 (https=)
KR (2) KR102413412B1 (https=)
CN (1) CN109195600A (https=)
AU (1) AU2017227705A1 (https=)
IL (2) IL299223A (https=)
WO (2) WO2017151775A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151775A1 (en) * 2016-03-01 2017-09-08 Intezyne Technologies Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
US20230024119A1 (en) * 2019-12-05 2023-01-26 Bold Therapeutics, Inc. Combined use of sodium trans-[tetrachloridobis(1h-indazole)ruthenate(iii)] and etomoxir for treating cancers
US11730750B2 (en) 2020-02-17 2023-08-22 University Of Kentucky Research Foundation Drugs for GRP78 cell surface translocation and Par-4 secretion
WO2021195763A1 (en) * 2020-03-30 2021-10-07 Bold Therapeutics Inc. Antiviral ruthenate(iii) therapeutics
CN118450895A (zh) * 2021-10-28 2024-08-06 博德疗法公司 反式-[四氯双(1h-吲唑)钌(iii)酸]钠改善蛋白酶体抑制剂抗性的用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130129840A1 (en) * 2010-07-18 2013-05-23 Niiki Pharma Inc. Combination therapy using a ruthenium complex

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2152084B1 (en) * 2007-06-11 2013-12-18 Niiki Pharma Inc. Method of manufacturing a ruthenium complex
AU2011323832B2 (en) * 2010-10-25 2016-06-02 Niiki Pharma Inc. Method of treating neuroendocrine tumors
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2017151775A1 (en) * 2016-03-01 2017-09-08 Intezyne Technologies Use of trans-[tetrachlorobis(1h-indazole)ruthenate (iii)] for the treatment of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130129840A1 (en) * 2010-07-18 2013-05-23 Niiki Pharma Inc. Combination therapy using a ruthenium complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. B. GIFFORD ET AL: ""Expression of GRP78, Master Regulator of the Unfolded protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma"", 《MOLECULAR CANCER THERAPEUTICS》 *
PATRA HEFFETER ET AL: ""The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo"", 《EUROPEAN JOURNAL OF CANCER》 *

Also Published As

Publication number Publication date
WO2017151775A9 (en) 2018-09-13
US20190038601A1 (en) 2019-02-07
WO2017151762A1 (en) 2017-09-08
JP6997919B2 (ja) 2022-01-18
JP7513574B2 (ja) 2024-07-09
AU2017227705A1 (en) 2018-10-18
EP3423055A4 (en) 2019-10-16
KR102413412B1 (ko) 2022-06-28
KR20220075450A (ko) 2022-06-08
US20240091196A1 (en) 2024-03-21
US11633380B2 (en) 2023-04-25
JP2023024618A (ja) 2023-02-16
EP3423055A1 (en) 2019-01-09
AU2017227705A9 (en) 2018-12-20
IL261384A (en) 2018-10-31
US20250387370A1 (en) 2025-12-25
KR20180130509A (ko) 2018-12-07
JP2021167360A (ja) 2021-10-21
US20210085647A1 (en) 2021-03-25
IL299223A (en) 2023-02-01
IL261384B2 (en) 2023-05-01
US10821095B2 (en) 2020-11-03
IL261384B1 (en) 2023-01-01
JP2019507166A (ja) 2019-03-14
WO2017151775A1 (en) 2017-09-08

Similar Documents

Publication Publication Date Title
CN109195600A (zh) 反式-[四氯双(1h-吲唑)钌(iii)酸盐]用于治疗癌症的用途
Jing et al. BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer
Fan et al. Metformin exerts anticancer effects through the inhibition of the Sonic hedgehog signaling pathway in breast cancer Retraction in/10.3892/ijmm. 2023.5227
Zaccagnino et al. Tumor-reducing effect of the clinically used drug clofazimine in a SCID mouse model of pancreatic ductal adenocarcinoma
Gao et al. Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression
US20160310531A1 (en) Combination of pharmaceutical preparations for tumor chemotherapy
Ma et al. Tetrandrine suppresses human glioma growth by inhibiting cell survival, proliferation and tumour angiogenesis through attenuating STAT3 phosphorylation
KR20220042087A (ko) 엠토르 신호전달 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물
CN109310757A (zh) 硝羟喹啉和其类似物与化学疗法和免疫疗法在癌症治疗中的组合用途
CN108498802B (zh) 用于治疗非小细胞肺癌的药物组合物及其制剂
Li et al. KLF4 suppresses anticancer effects of brusatol via transcriptional upregulating NCK2 expression in melanoma
Zhang et al. A novel mechanism of lung cancer inhibition by methionine enkephalin through remodeling the immune status of the tumor microenvironment
CN117679427A (zh) 药物组合物在制备治疗肿瘤耐药药物中的应用
Seo et al. The establishment of a growth-controllable orthotopic bladder cancer model through the down-regulation of c-myc expression
Lange et al. Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma
Wang et al. XPR1 promotes ovarian cancer growth and regulates MHC-I through autophagy
Wu et al. Anti-tumor outcome evaluation against non-small cell lung cancer in vitro and in vivo using PolyI: C as nucleic acid therapeutic agent
Blobner et al. PD-1 blockade does not improve efficacy of EpCAM-directed CAR T-cell in lung cancer brain metastasis
Ni et al. SB225002 enhances radiosensitivity in cervical cancer via direct neutrophil inhibition and tumor cell suppression
Hu et al. Taraxasterol stimulates apoptosis of BCa cells via restraining PI3K/AKT and epidermal growth factor receptor (EGFR).
KR20210107548A (ko) 엠토르 신호전달 억제제를 유효성분으로 포함하는 암의 예방 또는 치료용 약제학적 조성물
Zhou et al. Utidelone suppresses PDAC growth and enhances gemcitabine therapy by inducing immunogenic cell death
Patel et al. Decipher the role of cancer stem cells in colorectal cancer based on molecular pathology and its clinical significance
CN120585840A (zh) 一种抑制TRIM25和HIF-1α结合的化合物在制备治疗肿瘤药物中的应用
Ramos et al. Afatinib is active in osteosarcoma in vitro models

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190111

WD01 Invention patent application deemed withdrawn after publication